What is the role of macrolide therapy in type 1 chronic rhinosinusitis?

Role of Macrolides in Type 1 Chronic Rhinosinusitis

Macrolides should be considered as a therapeutic option for type 1 (non-type 2, non-eosinophilic) chronic rhinosinusitis, particularly in patients who have failed corticosteroid therapy, using a half-dose regimen for 24 weeks duration. 1

Patient Selection Criteria

The effectiveness of macrolide therapy hinges entirely on selecting the right patients. Macrolides work through immunomodulatory mechanisms targeting Th1-mediated neutrophilic inflammation, not through direct antimicrobial action 2, 3.

Ideal Candidates:

• CRS without nasal polyposis (CRSsNP) - this is the strongest predictor of success 1, 4
• Near-normal or low serum IgE levels 1, 5
• Neutrophil-dominant inflammation (type 1 endotype) 2
• Corticosteroid-resistant disease 1

Poor Candidates:

• CRS with nasal polyposis (CRSwNP) - macrolides show minimal benefit 4
• Type 2 inflammation with elevated eosinophils
• High IgE levels 5

Dosing and Duration

The 2025 AAO-HNS guideline acknowledges mixed evidence but identifies specific parameters for optimal outcomes 1:

• Dose: Half-dose regimen (not very low dose) - for example, azithromycin 250mg three times weekly or roxithromycin 150mg daily 4, 5
• Duration: 24 weeks minimum - shorter courses (8-12 weeks) show inferior results 4
• No significant difference between 14-membered (clarithromycin, roxithromycin) and 15-membered (azithromycin) ring macrolides 4

Evidence Quality and Nuances

The evidence base is limited but informative. Only two double-blind, placebo-controlled RCTs exist 1:

1. Roxithromycin study: Showed significant improvement in symptoms and nasal endoscopy in CRSsNP patients 5
2. Azithromycin study: Failed to show benefit at end of 12-week treatment, but interestingly showed delayed benefit at 12 weeks post-treatment (50% vs 9% improvement) 1

A 2019 meta-analysis of 608 patients found no overall benefit when all CRS subtypes were pooled together, but subgroup analysis revealed significant benefit specifically in CRSsNP (SMD = -0.64) and with 24-week duration (SMD = -1.68) 4.

Post-Surgical Context

The role of macrolides after endoscopic sinus surgery is questionable. A 2023 meta-analysis of 606 post-surgical patients found no significant improvement in quality of life (SNOT scores) or symptom severity (VAS scores), though modest improvement in nasal endoscopy scores was noted 6. This suggests macrolides may have limited additive benefit when surgery has already addressed anatomic and inflammatory factors.

Important Caveats

Contraindications:

• Screen for nontuberculous mycobacterial (NTM) disease before initiating therapy - if positive, macrolide prophylaxis is contraindicated due to resistance development risk 7
• Consider baseline ECG for QT interval assessment
• Assess for drug interactions (particularly with statins, warfarin)

Guideline Limitations:

The 2020 British Thoracic Society guideline explicitly excluded chronic rhinosinusitis from their scope 7, and macrolides are not licensed for long-term immunomodulatory use in CRS 7. The 2025 AAO-HNS guideline notes the evidence is "mixed" and does not make a strong recommendation 1.

Practical Algorithm

1. Confirm type 1 CRS: Low eosinophils, CRSsNP phenotype, low/normal IgE
2. Document corticosteroid failure: Adequate trial of intranasal corticosteroids
3. Screen for NTM: Sputum examination if risk factors present
4. Initiate half-dose macrolide: Azithromycin 250mg 3x/week or roxithromycin 150mg daily
5. Treat for 24 weeks minimum: Shorter durations are ineffective
6. Monitor for delayed response: Benefits may not appear until weeks after completion 1

The evidence supports macrolide use specifically in non-eosinophilic CRSsNP resistant to steroids, but clinicians must recognize this represents off-label use with moderate-quality supporting evidence at best.